about
HDAC inhibitors and immunotherapy; a double edged sword?Trial Watch-Immunostimulation with cytokines in cancer therapyIdentification of Salvia haenkei as gerosuppressant agent by using an integrated senescence-screening assayCombination therapy in combating cancer.Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growthAZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells.IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus.Targeting the tumor microenvironment to enhance antitumor immune responsesMacrophages promote benzopyrene-induced tumor transformation of human bronchial epithelial cells by activation of NF-κB and STAT3 signaling in a bionic airway chip culture and in animal models.Cellular and molecular targeting for nanotherapeutics in transplantation tolerance.Rejuvenating immunity: "anti-aging drug today" eight years later.Koschei the immortal and anti-aging drugsCirculating and tumor-infiltrating Tim-3 in patients with colorectal cancer.Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).EBV-associated hepatic smooth muscle tumor of uncertain biologic behavior after heart transplantation in a pediatric patient: case report.Immunostimulatory activity of lifespan-extending agents.Epstein-Barr virus-associated smooth muscle tumors in children following solid organ transplantation: a review.Low-dose controlled release of mTOR inhibitors maintains T cell plasticity and promotes central memory T cells.Protein-mediated viral latency is a novel mechanism for Merkel cell polyomavirus persistence.Low pH impairs complement-dependent cytotoxicity against IgG-coated target cells.Defective autophagy gets to the brain.Rapamycin in preventive (very low) doses.Trial Watch: Radioimmunotherapy for oncological indications.An encouraging progress report on the treatment of progeria and its implications for atherogenesis.
P2860
Q26853102-B129CD80-1C56-4E25-B27D-94DF85BA30ACQ28078725-D95837EE-4604-40DE-B719-994C90E0B72BQ28818070-BDDF6848-1FB5-4C90-B908-BCBB796D236AQ33914234-F9ACD4EB-D0DA-4914-BE64-2C0BB2AE4ADBQ34221890-8B30E617-3843-4AE9-82E0-50B1B4BCABB0Q34334399-1233531F-AD57-4016-AC55-56A59F1F7834Q34483744-62EBB60E-B891-44D8-98AF-409C39BCED85Q35176307-7C49F281-C997-4374-9C88-5911D518EC6DQ35832257-8C1E114F-190B-4ED1-A641-3C71C22195CCQ36011368-E9DC891F-1E67-4DE7-A7BC-E98F18FC2DCAQ36260537-79A0448E-F810-4DF6-826D-4EAA4471F36DQ36292001-D67C1605-E350-4421-BAFF-5A0251D9BF6FQ36299762-912D4350-99CF-4715-B907-18F44444E3A3Q36414149-E528D7FB-B916-453E-A373-5859ED797781Q37677567-3EC396CB-C424-4356-A921-3EAD1D1C627CQ38175673-D4092E6D-277D-49C0-B4C2-2A772DE5B65DQ38311957-CDC1A836-C07C-4139-B234-FFD3758166B2Q38930638-F0C50AD3-3943-43B7-80DA-54772443A22FQ40219805-AD7D2051-961D-49CA-A325-7EB66B281552Q41842699-0B4A6C7F-342E-4616-BEFC-DD357CA9D41DQ42552185-2928726D-22A7-492E-9A2D-5BF805696F61Q42558709-147DDED0-18C6-48A8-ABD7-B2B810895049Q43104064-C6A1A92C-D06C-460E-980B-7EDE1CC44C50Q43140936-E2E5B9C3-3B33-406C-8935-57F95E4E586E
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Immunosuppressants in cancer prevention and therapy
@en
Immunosuppressants in cancer prevention and therapy
@nl
type
label
Immunosuppressants in cancer prevention and therapy
@en
Immunosuppressants in cancer prevention and therapy
@nl
prefLabel
Immunosuppressants in cancer prevention and therapy
@en
Immunosuppressants in cancer prevention and therapy
@nl
P2860
P356
P1433
P1476
Immunosuppressants in cancer prevention and therapy
@en
P2860
P304
P356
10.4161/ONCI.26961
P577
2013-11-06T00:00:00Z